Bausch Health Companies Inc. (NYSE/TSX: BHC) has made significant changes to its executive leadership team (ELT), with the appointment of two new members.
Jean-Jacques Charhon ("JJ") will join the company as Chief Financial Officer on August 19, 2024. He brings over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech, and services, primarily at General Electric, Hewlett Packard, Novartis, and Purdue Pharma. Upon JJ’s arrival, John Barresi, the company’s interim Chief Financial Officer, will resume his role as SVP, Controller.
Aimee Lenar has already joined the company on July 15, 2024, as Executive Vice President, US Pharma. Her new role includes leadership of Salix Pharmaceuticals, Bausch Health’s gastroenterology (GI) business, as well as neurology, generics, market access, and commercial operations. Aimee brings over 20 years of experience in the pharmaceutical industry, most recently as head of US prescription medicine at Galderma.
These changes reflect the company’s ambition to be a globally integrated and innovative healthcare company, trusted and valued by patients, healthcare professionals, employees, and investors.
JJ, who was previously Executive Vice President and Chief Financial Officer at Signant Health, holds a master’s degree in business administration from the Solvay School of Management in Brussels, Belgium. Aimee, who joined from Galderma, holds a master’s degree in public health from Emory University.
Bausch Health Companies Inc. is a global diversified pharmaceutical company enriching lives through its relentless drive to deliver better healthcare outcomes. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health, through its controlling ownership of Bausch + Lomb Corporation. Today the company's shares have moved -3.1% to a price of $7.38. Check out the company's full 8-K submission here.
